Chronic prurigo in an adolescent patient successfully controlled with dupilumab.
Al-Abdulla MN, Al-Qahtani N, Younis SM, Rizvi S, Elfaieg A, Buddenkotte J, Steinhoff M
Skin Health and DiseaseIn the feed 1 Aug 2026, published online 29 Apr 2026, issue 2026 Aug, added to PubMed 1 Aug 2026
Topics: Itch & prurigoChildrenBiologics
Abstract
Chronic prurigo, formerly termed prurigo nodularis, is a chronic skin condition characterized by intensely itchy nodules and papules. It primarily affects adults, particularly middle-aged women. The aetiology of chronic prurigo is unclear, but it can be associated with primary skin dermatoses and systemic conditions. Minimal data on chronic prurigo in children are available in the literature. While systemic therapies for chronic prurigo have significant side effects, targeted biologic and small--molecule inhibitors offer a promising treatment option with a good benefit-risk ratio. We report one of the first cases of an adolescent with chronic prurigo that was successfully controlled with dupilumab. Dupilumab treatment resulted in a fast, significant and sustainable improvement in the signs and symptoms of chronic prurigo, with favourable safety and tolerability profiles, highlighting its potential for recalcitrant cases and long-term remission.
Abstract from PubMed
PMID 42540003 · DOI 10.1093/skinhd/vzag050